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THIS ISSUE’S AUTHORS
ALAN J. BUDNEY, PH.D., is a professor in the utilization among members of stigmatized groups, ROBERT S. STEPHENS, PH.D., is a professor
Department of Psychiatry and Behavioral Sciences including racial and ethnic minorities; the gay, les- of psychology at Virginia Polytechnic Institute. He
at the University of Arkansas for Medical Sciences. bian, bisexual, and transgendered population; and studies cognitive-behavioral and motivational
His research on treatments for adult and adoles- overweight and obese individuals.  enhancement approaches to the treatment of mar-
cent marijuana dependence and marijuana with- ijuana dependence and related problems. Recent
drawal syndrome has established the time course, ROGER ROFFMAN, D.S.W., is a professor at work includes evaluations of check-up approaches
pharmaco-specificity, and clinical significance of the University of Washington School of Social Work, as a means to reach marijuana users and attempts
marijuana withdrawal. His treatment development where he also directs the Innovative Programs to improve outcomes in treatment trials by extend-
research has focused on the use of innovative incen- Research Group. His research focuses on the design ing the duration and dose of treatment for users
tive programs to enhance abstinence outcomes dur- and evaluation of interventions in the fields of drug who do not respond initially or who relapse early.
ing and after treatment for marijuana abuse.  dependence, prevention of HIV infection, and inti-
mate partner violence. Along with Robert S. Stephens, DIANA SYLVESTRE, M.D., is an assistant clin-
MICHAEL DENNIS, PH.D., is the director of he edited Cannabis Dependence: Its Nature, ical professor of medicine at the University of
the Global Appraisal of Individual Needs Coordinating Consequences, and Treatment,published in 2006 by California, San Francisco; a specialist in addiction
Center and a senior research psychologist at Chestnut Cambridge University Press. In addition to inter- medicine; and the executive director and founder
Health Systems in Bloomington, Illinois. His research ventions designed for those seeking treatment, Dr. of the Organization to Achieve Solutions in Substance
interests include adolescent and adult substance Roffman’s recent research has focused on a brief Abuse (O.A.S.I.S.). She conducts research on hep-
abuse treatment, and long-term recovery manage- “taking stock” motivational enhancement therapy atitis C treatment in addicted patients. She is the
ment and methodology. He is the principal inves- tailored for individuals concerned about their behav- chair of the California Hepatitis Alliance and serves
tigator of the Early Reintervention experiments, ior, but not yet committed to change. on the Medical Advisory Board of the American
coordinating center principal investigator of the Liver Foundation and the Hepatitis Advisory Council
Cannabis Youth Treatment experiments, coprin- SHARON SAMET, M.S.W., M.PHIL.,is a research of the Hepatitis Foundation International. 
cipal investigator of the Pathways to Recovery study, scientist in the Department of Research Assessment
coinvestigator of the Assertive Counting Care exper- and Training of the New York State Psychiatric DENISE WALKER, PH.D.,is a research assistant
iments, chair of the Society for Adolescent Substance Institute. Her research and professional interests professor in the School of Social Work at the University
Abuse Treatment, and chair of the Data Safety include the co-occurrence of substance use disor- of Washington and clinical director of the Innovative
Monitoring  Board  for  NIDA’s  Division of ders with psychiatric disorders, diagnostic meas- Programs Research Group. Her research interests
Epidemiology Services and Prevention Research.  urement, and clinical social work. She is one of the include the development and evaluation of sub-
developers of the Psychiatric Research Interview stance abuse treatments and motivational inter-
DEBORAH S. HASIN, PH.D., is a professor of for Substance and Mental Disorders and a doctoral viewing interventions for adult and adolescent mar-
clinical public health and psychiatry at Columbia student at the Columbia University School of Social ijuana abuse, domestic violence, gambling, and
University and a research scientist at the New York Work. other problem behaviors.
State Psychiatric Institute. She has investigated sub-
stance abuse disorders, the comorbidity of drug CHRISTY K SCOTT, PH.D.,is the regional direc- RACHEL WAXMAN, B.A., is a doctoral student
dependence and other psychiatric disorders, and tor of Chestnut Health System’s Chicago research in clinical psychology at St. John’s University. She
gene–environment interaction. She is the lead devel- office, director of the Illinois Health Survey Laboratory, has worked as an assistant research scientist in the
oper of the Psychiatric Research Interview for and developer of the longitudinal followup model Department of Research Assessment and Training
Substance and Mental Disorders and a member of that has been used across multiple studies. Her of the New York State Psychiatric Institute. Her
the American Psychiatric Association’s workgroup research interests include recovery management, research and professional interests include child-
on substance use disorders for the Diagnostic and women’s treatment, homelessness, co-occurring hood predictors of psychopathology and related
Statistical Manual of Mental Disorders, 5th Edition. psychiatric problems, criminal justice, HIV risk, outcomes, comorbidity between Axis I and II
and methodology. She is the principal investigator disorders, and clinical assessment and treatment of
MARK HATZENBUEHLER, M.S., M.PHIL., of the Pathways to Recovery study, principal inves- children and adolescents.
is a doctoral student in clinical psychology at Yale tigator of the Recovery Management Checkups for
University. His research program seeks to under- Women Offenders experiment, and coprincipal
stand how stigma contributes to mental health dis- investigator of the Early Reintervention and Cannabis
parities, as well as disproportionate treatment Youth Treatment experiments. She serves on NIDA’s
Health Services Research Review Group.T H I S   I S S U E ’ S   A U T H O R S   •   5 9
JACK D. BLAINE, M.D., serves as a senior med-
ical consultant for NIDA’s National Drug Abuse
Treatment Clinical Trials Network and has a gen-
eral adult psychiatry private practice. He is board-
certified in psychiatry with a subspecialty certifi-
cation in addiction psychiatry. He has served in
numerous clinical and research capacities at the
University of California, Los Angeles; the National
Institute of Mental Health; NIDA; and the University
of California, San Diego. His research focuses on
the clinical effects of marijuana, as well as on behav-
ioral therapy and pharmacotherapy for drug depend-
ence.
ALLAN J. COHEN, M.A., M.F.T., is the direc-
tor of research and training for Bay Area Addiction,
Research, and Treatment, Inc., which operates a
network of 14 community treatment programs for
opioid dependence and other substance use disor-
ders. He  serves on the National Steering, Executive,
and Publications Committees of NIDA’s Clinical
Trials Network. He has been the coprincipal inves-
tigator on numerous research grants involving both
pharmacological and behavioral treatment inter-
ventions.
ROBERT F. FORMAN, PH.D., is a clinical sci-
entist for Alkermes, Inc., a biotechnology company
that develops medicines for addiction and other
diseases. As a clinician and administrator, he has
opened and managed more than 20 addiction treat-
ment programs. As a researcher, he has studied cli-
nician attitudes toward addiction and its treatment,
quality improvement interventions in addiction
treatment, and technology transfer, and he has
served as the principal investigator or coinvesti-
gator on several major clinical trials. Dr. Forman
is the author of two Substance Abuse and Mental
Health  Services  Administration  Treatment
Improvement Protocols and several addiction treat-
ment software applications.
RACHEL GONZALES, PH.D., has experience
in research and evaluation of substance use disor-
ders in both adolescent and adult populations.
Currently, she serves as the project director on
the state-funded California Outcome Measurement
System for the University of California, Los Angeles,
Integrated Substance Abuse Programs. She has
served as the codirector and codeveloper for an anti-
tobacco program for adolescents.
DANA MACKIN, M.A.,is a substance abuse and
domestic violence counselor at ChangePoint, Inc.,
in Portland, Oregon. She currently works with early
interventions, driving under the influence diver-
sion programs, and intensive outpatient clients.
Her interests include the intersection of addiction
and violence, particularly with regard to metham-
phetamine dependence. Her research focuses on
counselors’ perceptions of the therapeutic alliances
formed with dangerous clients.
CHRISTOPHER MARTIN, M.D., is an assis-
tant professor in the Menninger Department of
Psychiatry at Baylor College of Medicine. As a staff
psychiatrist and team leader with the Compass
Program for Young Adults at the Menninger Clinic
in Houston, Texas, he treats patients with complex
disorders of mood, anxiety, and personality that
often co-occur with substance-related disorders.
He is also interested in the interface of art and psy-
chiatry.
JILL K. McGAVIN, PH.D.,is the program direc-
tor of substance dependence and vocational reha-
bilitation at the Michael E. DeBakey Veterans
Administration Medical Center in Houston, Texas.
Services provided include detoxification, psychi-
atric care, opioid replacement treatment, psycho-
logical assessments, social work, addiction/relapse
prevention education and support groups, and case
management. Dr. McGavin is also an assistant pro-
fessor in the Department of Psychiatry and Behavioral
Sciences of Baylor College of Medicine. 
DAVID C. PERLMAN, M.D., is the associate
chief of infectious diseases and investigator in the
Baron Edmond de Rothschild Chemical Dependency
Institute at Beth Israel Medical Center in New York,
a professor of medicine at the Albert Einstein College
of Medicine, and the director of the Infectious
Diseases Core at the NIDA-funded Center for Drug
Use and HIV Research at National Development
and Research Institutes, Inc., in New York. His
research interests focus on clinical, epidemiologi-
cal, and health service aspects of tuberculosis, hep-
atitis, and other infections among drug users and
HIV-infected persons. He also practices in the field
of general infectious diseases. 
DACE SVIKIS, PH.D., is a professor in the
Department of Psychology, director of Promoting
Healthy Pregnancies in the Department of
Obstetrics/Gynecology, and deputy director of the
Institute  for  Women’s  Health  at  Virginia
Commonwealth University. She served as the direc-
tor of the Center for Addiction and Pregnancy at
The Johns Hopkins University School of Medi-
cine. She is currently the principal investigator
on a project funded by the Centers for Disease
Control and Prevention to improve patient com-
pliance with prenatal care and serves as the princi-
pal investigator on a project to examine different
strategies for preventing HIV infection and other
sexually transmitted diseases in pregnant drug-
abusing women.
WILLIAM M. “MEL” TAYLOR, M.S.W.,is pres-
ident and chief executive officer of the Council on
Alcohol and Drugs in Houston, Texas. The Council
has received numerous best practice awards, most
recently the Gold Award for outstanding commu-
nity programs from the American Psychiatric
Association. The Council touches the lives of more
than 200,000 individuals each year through brief
interventions, motivational counseling, and school-
based prevention, and adult intensive outpatient
treatment. Mr. Taylor also serves on numerous state
and national committees on behavioral health. 
CLAUDETTE WALLACE, M.A., has worked as
a counselor, supervisor, program developer, inter-
ventionist, and consultant. In 1985, she developed
a 12-month, day-treatment program for women
and children. She worked for Springbrook (now
Hazelden Springbrook) as a supervisor of outpa-
tient services, supervisor of residential co-ed treat-
ment services, and evaluation specialist working
with licensing boards all over the United States. In
addition, she provided services for offenders in
Oregon State corrections facilities. She is currently
on staff at ChangePoint, Inc., where she is a researcher
on methamphetamine addiction and a counselor.
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